TNFSF11 and ovarian cancer: For example, Pin et al. (2022) reported that elevated systemic RANKL levels were linked to musculoskeletal deterioration in both animal models and human subjects with non-metastatic ovarian cancer and cachexia, pointing to a tumor-driven mechanism contributing to both bone and muscle degradation—even in the absence of metastases [24].